Zhang H T
Cancer Institute, Haerbin Medical College.
Zhonghua Zhong Liu Za Zhi. 1988 Sep;10(5):342-5.
SHR rats, 1 week of age, were i.p. inoculated with allogeneic JB LAK cells generated by 3-day incubation of spleen cells of JB rats in CM-IL 2. The spleens were removed 4 and 12 weeks later and their cells were tested for proliferative potential to mitogens and their response and production of IL2. The results demonstrated that the allo-LAK recipients showed no signs of acute or chronic GvH disease but showed immune response equivalent to or higher than the normal controls. Severe functional defects were observed in the newborn SHR rats after i.p. inoculation of allogeneic fresh spleen cells from JB rats. The results strongly suggest that allogeneic LAK cells be ineffective in terms of induction of GvH disease or GvH associated immunodeficiencies (GvHID). Therefore, this might be promising in clinical trials on cancer adoptive immunotherapy with allogeneic, instead of autologous, LAK cells.
1周龄的SHR大鼠经腹腔接种通过将JB大鼠的脾细胞在CM-IL 2中培养3天产生的同种异体JB LAK细胞。4周和12周后取出脾脏，检测其细胞对丝裂原的增殖潜力以及它们对IL2的反应和产生情况。结果表明，同种异体LAK细胞受体没有急性或慢性移植物抗宿主病的迹象，但显示出与正常对照相当或更高的免疫反应。在腹腔接种来自JB大鼠的同种异体新鲜脾细胞后，新生SHR大鼠中观察到严重的功能缺陷。结果强烈表明，同种异体LAK细胞在诱导移植物抗宿主病或移植物抗宿主相关免疫缺陷（GvHID）方面无效。因此，这可能在使用同种异体而非自体LAK细胞进行癌症过继免疫治疗的临床试验中具有前景。
